Activated MMP-8 as Diagnostic Test for Periodontitis
MMP-8
Activated Matrix Metalloproteinase 8 (aMMP-8) in Saliva as Diagnostic Test for Periodontal Disease? A Case-control Study
1 other identifier
observational
60
0 countries
N/A
Brief Summary
Background: Untreated periodontal disease may influence general health. However, how may a physician who is not trained in periodontal probing detect untreated periodontitis? Activated matrix metalloproteinase-8 (aMMP-8) in saliva correlates with periodontal probing parameters. Thus, sensitivity and specificity of a chair-side test for activated matrix metalloproteinase-8 to detect periodontitis was evaluated. Methods: Thirty cases (untreated chronic periodontitis; 15 generalized moderate and 15 generalized severe) and 30 controls (probing pocket depths ≤ 3 mm, vertical probing attachment level ≤ 2 mm at \< 30% of sites) were examined periodontally. Further, the activated matrix metalloproteinase-8 test was performed. The test kit becomes positive with ≥ 25 ng/ml activated matrix metalloproteinase-8 in the sample.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Sep 2012
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2014
CompletedFirst Submitted
Initial submission to the registry
October 29, 2014
CompletedFirst Posted
Study publicly available on registry
October 31, 2014
CompletedResults Posted
Study results publicly available
June 4, 2015
CompletedJuly 13, 2015
July 1, 2015
1.4 years
October 29, 2014
May 19, 2015
July 8, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of True Positive/Negative aMMP-8 Tests of All Periodontitis Patients (Sensitivity/Specificity)
First off all patients rinsed with tap water for 30 seconds. Then they spat out the water and waited for 1 min. Now patients rinsed with 5ml of purified water for 30 seconds and spat this sample back into the test cup. Approximately 2 ml of the sampled saliva was now sampled with a syringe. After a filter was put onto the syringe 3 drops of the saliva were pressed through the filter into the ELISA kit. After 5 to 10 min the result was read from the test kit \[21\]. If both the control and test stripes were visible the respective test was positive (i.e. ≥ 25 ng aMMP 8 per ml). The clinical examiner (SIB) judged the results by simple visual inspection. Already a faint test stripe was judged as positive test. All test results were photographed with 2fold magnification. All images of the test were then evaluated by a second examiner (PE) who was blinded for the clinical diagnoses.
5 minutes
Study Arms (2)
gen. mod. to sev. chronic periodontitis
* Sites with probing pocket depths (PPD) ≥ 3.5 mm * Attachment loss (PAL-V) ≥ 3 mm \> 30% of sites * no Intervention provided
periodontally healthy
* PPD ≤ 3 mm * PAL-V ≤ 2 mm at \< 30% of sites * BOP \< 20% * No radiographically detectable bone loss: distance cemento-enamel junction to provided * no Intervention but aMMP-8 test
Interventions
No Intervention was rendered but the aMMP-8 test was made
Eligibility Criteria
Periodontally healthy individuals and patients with untreated generalized moderate and generalized severe ChP from a German dental Office in Frankfurt/Main
You may qualify if:
- At least18 years of age
- Clinical diagnosis of generalized moderate or generalized severe ChP
- At least 5 teeth present per quadrant
- After application to the ethics committee: written informed consent
You may not qualify if:
- Requirement of systemic antibiotics for measures that may cause transitory bacteraemia (e.g. pocket probing)
- Nonsurgical or surgical periodontal treatment within the last 12 months prior to PerioMarker® test
- Systemic or topical subgingival antibiotics within the last 6 months prior to PerioMarker® test
- Anti-inflammatory medication (e.g. non-steroidal anti-inflammatory drugs) during the last 3 months prior to PerioMarker® test
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Izadi Borujeni S, Mayer M, Eickholz P. Activated matrix metalloproteinase-8 in saliva as diagnostic test for periodontal disease? A case-control study. Med Microbiol Immunol. 2015 Dec;204(6):665-72. doi: 10.1007/s00430-015-0413-2. Epub 2015 Apr 5.
PMID: 25841875RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
The aMMP-8 test is sensitive to distinguish untreated periodontally diseased from healthy individuals. However, this study does not provide information how clearly the test may distinguish between gingivitis and untreated chronic periodontitis.
Results Point of Contact
- Title
- Prof. Dr. Peter Eickholz
- Organization
- JWGUniversity
Study Officials
- STUDY CHAIR
Peter Eickholz, Dr.
Johann Wolfgang Goethe-Universität
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. med. dent.
Study Record Dates
First Submitted
October 29, 2014
First Posted
October 31, 2014
Study Start
September 1, 2012
Primary Completion
February 1, 2014
Study Completion
February 1, 2014
Last Updated
July 13, 2015
Results First Posted
June 4, 2015
Record last verified: 2015-07